VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

L. amazonensis CP Protein Vaccine L. amazonensis DNA vaccine encoding GP46 L. amazonensis DNA vaccine encoding WD protein L. amazonensis M2 protein vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004199
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: A 500 bp fragment encoding an isoform of cysteine proteinase (CP) from Leishmania (Leishmania) amazonensis was subcloned and expressed in the pHis vector, resulting in a recombinant protein of 24 kDa, rLacys24 (Fedeli et al., 2010).
  • CP cysteine proteinase gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Immunization Route: subcutaneous injection
  • Vaccine Ontology ID: VO_0011354
  • Type: DNA vaccine
  • Status: Research
  • Antigen: L. amazonensis gp46
  • Gp46 gene engineering:
    • Type: DNA vaccine construction
    • Description: cDNAs encoding L. m. amazonensis gp46 antigen was subcloned into the VR1012 plasmid (Dumonteil et al., 2000)
    • Detailed Gene Information: Click Here.
  • Vector: VR1012 plasmid
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0011349
  • Type: DNA vaccine
  • Status: Research
  • Antigen: L. amazonensis WD
  • WD gene engineering:
    • Type: DNA vaccine construction
    • Description: The whole gene insert from the pBK-CMV clone containing the LAWD gene was subcloned into the pET32a plasmid (Invitrogen) for His tag protein expression. To ensure that the ORF would be read in frame, the plasmid was first digested with BamHI and then blunt-ended by a Klenow reaction (Invitrogen) (Campbell et al., 2004).
    • Detailed Gene Information: Click Here.
  • Vector: pcDNA3.1/Hygro(−) (Invitrogen)
  • Immunization Route: Subcutaneous injection
  • Vaccine Ontology ID: VO_0011355
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: L. amazonensis M2
  • M2 gene engineering:
    • Type: Recombinant protein preparation
    • Description: M-2, a 46-kDa promastigote-specific glycoprotein was isolated. The protein was further purified by removal of detergent with an anionexchange column(Champsi and McMahon-Pratt, 1988).
    • Detailed Gene Information: Click Here.
  • Adjuvant: killed Corynebacterium parvum vaccine adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Female BALB/c mice (six per group) were immunized thrice with a 2 week interval with 25 μg of rLacys24 plus complete Freund’s adjuvant (CFA) by the subcutaneous route in the base of the tail. Control animals received PBS or only adjuvant (Fedeli et al., 2010).
  • Challenge Protocol: Two weeks after the last dose animals were challenged with 2.5 × 105 L. (L.) amazonensis amastigotes in PBS in the hind footpad (Fedeli et al., 2010).
  • Efficacy: Immunization of BALB/c mice with rLacys24 plus CFA adjuvant resulted in a low but significant decrease of foot lesions after challenge with L. (L.) amazonensis compared to those exhibited by control mice (Fedeli et al., 2010).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Susceptible BALB/c mice were immunised with two i.m. injections of 100 microg of plasmid DNA (Dumonteil et al., 2000).
  • Challenge Protocol: Mice were challenged by the injection of 4 x 106 L. m. mexicana parasites in the foot pad to evaluate protection (Dumonteil et al., 2000).
  • Efficacy: Measurement of lesion size indicated that mice immunised with VR012-GP46 were partially protected against infection (Dumonteil et al., 2000).

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice (five per group) were immunized in five locations with a total of 100 μg of DNA (50 μg of LAWD and 50 μg of IL-12) per mouse: four injections in both sides of the inner and outer thigh muscles of the hind legs (∼50 μl/site) and one subcutaneous injection in the left hind foot (∼5 μl/site) (Campbell et al., 2004).
  • Challenge Protocol: Mice were boosted twice at 3-week intervals and then challenged 3 weeks after the last immunization with 2 × 105 metacyclic promastigotes in the right hind foot (Campbell et al., 2004).
  • Efficacy: DNA vaccination in BALB/c mice with the LAWD (for Leishmania antigenic WD protein) and IL-12 genes significantly delayed lesion development from challenge with Leishmania amazonensis, which correlated with a dramatic reduction in parasite burdens (Campbell et al., 2004).

Mouse Response

  • Host Strain: CBA
  • Vaccination Protocol: BALB/c, CBA, and C57BL/6 mice were immunized intraperitoneally with M-2 at a final concentration of 0.03 mg/ml. The amount of C. parvum used in immunizations 2 and 3 was reduced to 0.05 mg per immunization (Champsi and McMahon-Pratt, 1988).
  • Challenge Protocol: Animals were rested for 2 to 4 weeks after final immunization and challenged in the right hindfoot with late-log-phase promastigotes. Parasites used for infections were passaged a maximum of four times. Challenge doses of 103, 104, 105, and 106 were used (Champsi and McMahon-Pratt, 1988).
  • Efficacy: Immunization of CBA mice with the M-2 glycoprotein of L. amazonensis and C. parvum adjuvant resulted in complete protection against a challenge infection of 104 and 106 late log-phase promastigotes of L. amazonensis. In the BALB/c strain, complete protection was observed in some of the immunized animals (28 to 50%); in the rest of the mice the onset of infection was significantly delayed. Protective immunity for C57BL/6 mice was observed only at the low infecting dose (10(4) L. amazonensis organisms) (Champsi and McMahon-Pratt, 1988).
References References References References
Fedeli et al., 2010: Fedeli CE, Ferreira JH, Mussalem JS, Longo-Maugéri IM, Gentil LG, dos Santos MR, Katz S, Barbiéri CL. Partial protective responses induced by a recombinant cysteine proteinase from Leishmania (Leishmania) amazonensis in a murine model of cutaneous leishmaniasis. Experimental parasitology. 2010; 124(2); 153-158. [PubMed: 19735658].
Dumonteil et al., 2000: Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J, Ramirez-Sierra MJ, Valencia-Pacheco G, Flores-Serrano A, Canto-Lara S, Arjona-Torres A. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Developments in biologicals. 2000; 104; 135-141. [PubMed: 11713811].
Campbell et al., 2004: Campbell K, Popov V, Soong L. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein. Infection and immunity. 2004; 72(4); 2194-2202. [PubMed: 15039343].
Champsi and McMahon-Pratt, 1988: Champsi J, McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infection and immunity. 1988; 56(12); 3272-3279. [PubMed: 3182080].